Highly-sensitive tumour test under development:
This article was originally published in Clinica
Stem cell company Nexell Therapeutics has begun a two-year, multicentre study of a monoclonal antibody-based column for tumour cell enrichment, which forms the basis of a laboratory test for individual tumour cells. The test, which will be developed with the aid of a $535,000 grant from the US National Institutes of Health, will be used to detect breast, prostate and lung cancer metastases, said Irvine, California-based Nexell. Preclinical studies showed a sensitivity of one cell per 100 million blood cells, said the company.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.